Moderna and Merck report successful Phase 3 trial for melanoma vaccine

Pharmaceutical companies Moderna and Merck have announced positive results from a Phase 3 clinical trial involving more than 1,100 patients with melanoma, the most dangerous form of skin cancer. The study tested an experimental personalized mRNA vaccine known as intismeran autogene, administered in combination with Merck's immunotherapy drug, Keytruda. The results demonstrated a 42% reduction in the relative risk of melanoma recurrence or death, and a 38% reduction in the risk of distant metastases or death, based on approximately two years of follow-up data.

This development represents a significant advancement in oncology, as the vaccine is tailored to the specific genetic mutations found in each patient’s tumor. Experts, including Dr. Nikos Zamboglou of the German Oncology Centre, highlighted that while melanoma was previously considered a dire diagnosis, these personalized medical advancements offer new hope for life extension and potential cures. The detailed findings from this study are scheduled to be presented on Saturday, October 24, at the European Society for Medical Oncology (ESMO) congress in Madrid. Further research remains necessary to determine long-term benefits and accessibility.